CM/PHR/23/5702 - NHS National Framework for Tocilizumab - March 2024
Who
| Buyer | 02182135 — not a council we hold |
| Supplier | Fresenius Kabi Limited |
| Supplier | Roche Products Ltd |
What
Project Title: NHS National Framework for Tocilizumab - March 2024 Offer reference number: CM/PHR/23/5702 CM/PHR/23/5702/01 NHS Framework for Tocilizumab LONDON and SOUTH OF ENGLAND. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/23/5702/02 NHS Framework for Tocilizumab NORTH OF ENGLAND and MIDLANDS AND EAST. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
Dates and source
| Runs | 1 Mar 2024 to 28 Feb 2025 |
| OCID | ocds-b5fd17-57b54e85-da9c-4332-bb93-8a7359735da5 |
| Notice | Read it on Contracts Finder |
Figures are as published An award value in OCDS may be a framework ceiling rather than a sum anyone expects to spend, so a large figure here is not evidence of a large purchase.